Dr. Reddy's gets Health Canada approval for generic Semaglutide Injection

Dr. Reddy's Laboratories Ltd. announced on April 29, 2026, that it received a Notice of Compliance (NOC) from Health Canada for its Abbreviated New Drug Submission (ANDS) of Semaglutide Injection. This approval authorizes the commercialization, sale, and distribution of Semaglutide Injection in Canada. Dr. Reddy's is the first company to receive market authorization for generic Semaglutide Injection in Canada, covering 2 mg/pen and 4 mg/pen. This milestone highlights the company's expertise in complex generics and peptide-based therapeutics, supported by in-house API production. Canada is the world's second-largest market for Semaglutide, and this approval will help expand access to affordable GLP-1 treatments for Canadian diabetes patients.